International Psoriasis Council
Advancing Knowledge. Improving Care.
Palmoplantar pustulosis (PPP) is a challenging inflammatory skin disease often misclassified as psoriasis. Dr. José-Manuel Carrascosa Carrillo shares clinical perspectives
This expert overview by IPC Junior Councilor María Julia Cura examines palmoplantar pustulosis as a distinct inflammatory disease with evolving
Expert dermatologist Professor Ryan discusses the link between psoriasis and malignancy, treatment safety, and best practices for patients with a
In this IPC Expert Insights article, Dr. Matthew Vesely examines cancer risk in psoriasis and provides insights on safe, effective
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes
Learn about the relationship between psoriasis, obesity, and systemic inflammation, and how GLP-1 agonists, originally developed for type 2 diabetes
This article examines the unique impact of psoriasis on individuals assigned female at birth, particularly during pregnancy and menopause, highlighting
This article examines the unique impact of psoriasis on individuals assigned female at birth, particularly during pregnancy and menopause, highlighting
IPC Councilor Ulrich Mrowietz, founder of the Psoriasis Center at University Medical Center Schleswig-Holstein, discusses psoriasis as a systemic disease
Psoriasis patients face the challenges of visible skin disease and the risks of developing related comorbidities. This article explores the
Psoriasis in older patients presents unique challenges. This article discusses treatment considerations, risks of side effects, and best practices for
Psoriasis in older patients presents unique challenges and treatment considerations. Learn about the prevalence of topical therapies, phototherapy, and systemic
Learn from Dr. Steven Feldman, a renowned expert in psoriasis treatment, about the importance of patient adherence. Discover practical strategies
Learn the dynamics of psoriasis treatments, emphasizing patient adherence challenges. From evolving therapies to oral and biologic agents, understand real-world
Explore the challenges, solutions, and breakthroughs in improving psoriasis treatment adherence. Discover the latest strategies and steroid-free topical agents transforming
In this enlightening blog post, Dr. Andrew Alexis, an esteemed Professor of Clinical Dermatology, delves into the intricacies of diagnosing
Discover the latest insights on psoriasis treatment for individuals with skin of color in our comprehensive blog post. Learn about
This blog post provides a comprehensive overview of psoriasis in individuals with skin of color. It explores the prevalence of
The spread of COVID-19 in early 2020 brought many concerns and questions about COVID-19 and psoriasis. To help address these
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making
In 2022, IFPA and IPC announced a new partnership to join their clinical expertise and the patient perspective. Here’s what
The patient perspective has become even more important in the wake of the pandemic. Here’s how Clinica Dermacross is making
La investigación de la Dra. Kelly Cordoro sobre la psoriasis pediátrica muestra que puede ser hora de repensar nuestras expectativas
A pesquisa da Dra. Kelly Cordoro sobre psoríase pediátrica mostra que talvez seja hora de repensar nossas expectativas sobre comorbidades
Dr. Kelly Cordoro’s research on pediatric psoriasis shows it may be time to rethink our expectations about comorbidities and treatment.
El Proyecto de Reclasificación de la Severidad de la Psoriasis de los Consejos Internacionales de Psoriasis tiene como objetivo cambiar
O Projeto de Reclassificação da Gravidade da Psoríase do Conselho Internacional de Psoríase visa alterar a classificação da gravidade da
International Psoriasis Councils’ Psoriasis Severity Reclassification Project aims to change the classification of psoriasis severity. IPC’s network of key opinion
Erupções recorrentes, pele vermelha e dolorosa e pústulas estéreis são as características da psoríase pustulosa generalizada (PPG), uma doença autoinflamatória
Los brotes recurrentes, la piel dolorosa de color rojo fuego y las pústulas estériles son las características de la psoriasis
Recurrent flares, painful fiery-red skin, and sterile pustules — are the characteristics of Generalized Pustular Psoriasis (GPP), a rare and
Biológicos e biossimilares criaram muitas novas opções no tratamento da psoríase para pacientes em todo o mundo, mas os pacientes
Los productos biológicos y biosimilares han creado muchas opciones nuevas en el tratamiento de la psoriasis para pacientes de todo
Biologics and biosimilars have created many new options in psoriasis treatment for patients worldwide, but patients worldwide face barriers to
The monkeypox outbreak has had a significant impact all across the globe. Here’s what to know about monkeypox symptoms, treatment,
A psoríase e a tuberculose há muito andam de mãos dadas. Isto é especialmente verdade em certas partes do mundo,
La psoriasis y la tuberculosis han ido de la mano durante mucho tiempo. Esto es especialmente cierto en ciertas partes
Psoriasis and tuberculosis have long gone hand-in-hand. This is especially true in certain parts of the world, where latent tuberculosis
Prof. Christine Bundy shares how clinicians can center mental health in psoriasis care — and what to look out for
Personalized care has become increasingly utilized in the past two few decades, evolving as we have gained a greater understanding
Patients with psoriasis are at increased risk for cardiovascular disease —and lack of physical activity may be a driving cause.
In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.
What were the key takeaways from the 2026 AAD Annual Meeting? IPC shares updates on diagnostic challenges, psoriasis therapies, and late-breaking research from leading experts.
A new regional collaboration led by IPC and partner organizations aims to improve diagnosis, treatment, and care coordination for psoriasis and psoriatic arthritis across Latin America.
IPC recognizes its 2025 Fellows as IPC Jr. Councilors following the completion of their fellowship. This transition recognizes their contributions to psoriasis research, education, and global collaboration, and marks their expanded role in the IPC network.
The International Psoriasis Council welcomes Mari Løset and Maxwell Sauder as new Councilors, supporting IPC’s global mission in psoriasis research and care.
In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.